Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab in Black participants with pMMR endometrial cancer
NCT05263492Phase 2Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib and pembrolizumab in endometrial cancer (EC), sponsored by Virginia Commonwealth University. Started Apr 2022; status: terminated.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05263492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263492.